Fertility and Sterility
Volume 91, Issue 5 , Pages 1848-1852 , May 2009

Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome

  • Kathleen Brennan, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, the David Geffen School of Medicine at UCLA, Los Angeles, California
    • ,
  • Andy Huang, M.D., M.B.A.

      Affiliations

    • Department of Obstetrics and Gynecology, the David Geffen School of Medicine at UCLA, Los Angeles, California
    • ,
  • Ricardo Azziz, M.D., M.B.A., M.P.H.

      Affiliations

    • Department of Obstetrics and Gynecology, the David Geffen School of Medicine at UCLA, Los Angeles, California
    • Department of Medicine, the David Geffen School of Medicine at UCLA, Los Angeles, California
    • Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California
    • Corresponding Author InformationReprint requests: Ricardo Azziz, M.D., M.P.H., M.B.A., Department of Ob/Gyn and Center for Androgen Related Disorders, Cedars-Sinai Medical Center, 8635 West Third Street, Suite 160W, Los Angeles, CA 90048 (FAX: 310-423-3470).

Received 27 September 2007 ,Revised 4 February 2008 ,Accepted 8 February 2008.

References 

  1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078–3082
  2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: a hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84:4006–4011
  3. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434–2438
  4. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–2749
  5. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83:1454–1460
  6. Yucel A, Noyan V, Sagsoz N. The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2006;126:81–86
  7. Barbieri Rl, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 1986;62:904–910
  8. Nestler HE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositol-glycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998;83:2001–2005
  9. Buyalos RP, Bradley EL, Judd HL, Zacur HA, Azziz R. No acute effect of physiologic insulin increase on dehydroepiandrosterone sulfate in women with obesity and/or polycystic ovarian disease. Fertil Steril. 1991;56:1179–1182
  10. Hines GA, Smith ER, Azziz R. Influence of insulin and testosterone on adrenocortical steroidogenesis in vitro: preliminary studies. Fertil Steril. 2001;76:730–735
  11. Yamashita R, Saito T, Satoh S, Aoki K, Kuburagi Y, Sekihara H. Effects of dehydroepiandrosterone on gluconeogenic enzymes and glucose uptake in human hepatoma cell line, HepG2. Endocrinol J. 2005;52:727–733
  12. Buffington CK, Given JR, Kiabchi AE. Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity. In vivo and in vitro studies of hyperandrogenic females. Diabetes. 1991;40:693–700
  13. Mottl R, Cerman J. A relationship between dehydroepiandrosterone sulfate and insulin resistance in obese men and women. Vnitr Lek. 2004;50:923–929
  14. Barrett-Connor K, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986;315:1519–1524
  15. Mitchell LE, Sprecher DL, Borecki IB, Rice T, Laskarzewki PM, Rao DC. Evidence for an association between dehydroepiandrosterone sulfate and nonfatal premature myocardial infarction in males. Circulation. 1994;89:89–93
  16. Feldman HA, Johannes CB, Arauajo AB, Mohr BA, Longcope C, McKinay JB. Low dehydroepiandrosterone and ischemic heart diseases in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol. 2001;153:79–89
  17. Kameda W, Daimon M, Oizumi T, Jimbu Y, Kimura M, Hirata A, et al. Association of decrease in serum dehydroepiandrosterone sulfate levels with the progression to type 2 diabetes in men of a Japanese population: the Fungata Study. Metabolism. 2005;54:669–676
  18. Orentreich N, Brind HL, Rixer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59:551–555
  19. Fink RI, Kolterman OG, Griffin J, Olefsky JM. Mechanism of insulin resistance in aging. J Clin Invest. 1983;71:1523–1535
  20. Rowe JW, Minaker KL, Pallotta HA, Flier JS. Characterization of the insulin resistance in aging. J Clin Invest. 1983;71:1581–1587
  21. Paolisso G, Ammendola S, Rotandi M, Gambardella A, Rizzo MR, Mazziotti G, et al. Insulin resistance and advancing age: what role for dehydroepiandrosterone sulfate?. Metabolism. 1997;46:1281–1286
  22. Allolio B, Arlt W. DHEA treatment: myth or reality?. Trends Endocrinol Metab. 2002;13:288–294
  23. Coleman DL, Leiter EH, Schwizer RW. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes. 1982;31:830–833
  24. Azziz R. Evaluation for insulin resistance and co-morbidities related to insulin resistance in PCOS. In:  Nestler JE,  Diamanti-Kanarakis E,  Pasquali R,  Panidis D editor. Insulin resistance and polycystic ovarian syndrome: pathogenesis, evaluation, and treatment. New York: Human Press; 2007;p. 145–157
  25. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In:  Dunaif A,  Givens JR,  Haseltine F,  Merriam GR editor. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992;p. 377–384
  26. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25
  27. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47
  28. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237–4245
  29. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140:815–830
  30. Azziz R, Bradley EL, Potter HD, Parker CR, Boots LR. Chronic hyperinsulinemia and the adrenal androgen response to acute corticotropin-(1-24) stimulation in hyperandrogenic women. Am J Obstet Gynecol. 1995;172:1251–1256
  31. Pearlman WH, Crepy O, Murphy M. Testosterone-binding levels in the serum of women during the normal menstrual cycle, pregnancy, and the postpartum. J Clin Endocrinol Metab. 1967;27:1012–1018
  32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  33. Yildiz BO, Azziz R. The adrenal and polycystic ovary syndrome. Rev Endocrinol Metab Disord. 2007;8:331–342
  34. Farah-Eways L, Reyna R, Knochenbauer ES, Bartolucci AA, Azziz R. Glucose action and andrenocortical biosynthesis in women with polycystic ovary syndrome. Fertil Steril. 2004;81:120–125
  35. Diamonti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:1273–1276

 R. A. is a consultant for Merck & Co., Pfizer, Procter & Gamble, and Quest Diagnostics. K.B. has nothing to disclose. A.H. has nothing to disclose.

 Supported in part by National Institutes of Health grants R01-HD2364 and K24-HD01346-01, and the Helping Hand of Los Angeles, Inc., Los Angeles, California.

 Presented in part at the 62nd Annual Meeting of the American Society for Reproductive Medicine, New Orleans, LA, October 21–25, 2006.

PII: S0015-0282(08)00366-X

doi: 10.1016/j.fertnstert.2008.02.101

Fertility and Sterility
Volume 91, Issue 5 , Pages 1848-1852 , May 2009

Article Tools

* Image Usage & Resolution